Turn Therapeutics Inc(TTRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.29 | Insider Own | 63.78% | Shs Outstand | 29.8M | Perf Week | 1.46% |
| Market Cap | 0.32B | Forward P/E | - | EPS next Y | 4.55% | Insider Trans | - | Shs Float | 11.1M | Perf Month | -21.64% |
| Enterprise Value | 0.31B | PEG | - | EPS next Q | -0.09 | Inst Own | 3.93% | Short Float | 3.9% | Perf Quarter | 17.99% |
| Income | -0.01B | P/S | - | EPS this Y | -266.67% | Inst Trans | 21.83% | Short Ratio | 4.1 | Perf Half Y | 174.47% |
| Sales | 0.00B | P/B | 452.3 | EPS next 5Y | - | ROA | -76.99% | Short Interest | 0.43M | Perf YTD | 164.72% |
| Book/sh | 0.02 | P/C | 30.95 | EPS past 3/5Y | 29.26% - | ROE | -543.37% | 52W High | -36.6% ($16.45) | Perf Year | 99.05% |
| Cash/sh | 0.34 | P/FCF | - | Sales past 3/5Y | - | ROIC | -124.96% | 52W Low | 305.82% ($2.57) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -117.37% | Gross Margin | - | Volatility(W/M) | 8.76% 8.37% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.96 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.19 | EPS Q/Q | -117.74% | Profit Margin | - | RSI (14) | 43.37 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.19 | Sales Q/Q | - | SMA20 | -5% ($10.98) | Beta | 1.66 | Target Price | $20 |
| Payout | - | Debt/Eq | 8.87 | Earnings | 2026/8/12 | SMA50 | -11.04% ($11.72) | Rel Volume | 1.3 | Prev Close | $10.72 |
| Employees | 2 | LT Debt/Eq | 8.8 | EPS/Sales Surpr. | -900% - | SMA200 | 48.97% ($7) | Avg Volume(3M) | 0.11M | Price | $10.43 |
| IPO | 2025/10/8 | Option/Short | Yes/Yes | Trades | 2010 | Volume | 137,082 | Change | -2.71% |
🧬 Turn Therapeutics (TTRX) is a clinical-stage biotech company developing treatments for dermatological, advanced wound, and infectious diseases. The company holds clinical programs for conditions such as eczema and onychomycosis, along with its PermaFusion delivery platform, and is headquartered in the US, pursuing a commercialization strategy through medical distribution partnerships.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded more than usual. That is 130% of its average volume.
TTRX has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -266.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% It ranks #258 of 597 in the industry
Based on market cap of $318M.
ALEC#257 Alector Inc $328M PER - TTRX#258 Turn Therapeutics Inc $318M PER - 
ARCT#259 Arcturus Therapeutics Holdings Inc $314M PER - 
ENTA#260 Enanta Pharmaceuticals Inc $312M PER - 
PRLD#261 Prelude Therapeutics Inc $310M PER - 
FAQ
What kind of company is TTRX?
TTRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TTRX?
The market cap of TTRX is approximately $318M, ranking 3,573 within its sector.
What is the 52-week high and low for TTRX?
TTRX has recorded a 52-week high of $16.45 and a low of $2.57.
